| Literature DB >> 20092651 |
Carmen Fernandez-Becerra1, Sergi Sanz, Marina Brucet, Danielle I Stanisic, Fabiana P Alves, Erney P Camargo, Pedro L Alonso, Ivo Mueller, Hernando A del Portillo.
Abstract
BACKGROUND: Progress towards the development of a malaria vaccine against Plasmodium vivax, the most widely distributed human malaria parasite, will require a better understanding of the immune responses that confer clinical protection to patients in regions where malaria is endemic.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20092651 PMCID: PMC2835717 DOI: 10.1186/1475-2875-9-29
Source DB: PubMed Journal: Malar J ISSN: 1475-2875 Impact factor: 2.979
Figure 1Diagram representing the concordance between BioPlex and ELISA assays.
Figure 2Correlation between the results from BioPlex and ELISA using the Spearman's rank correlation test. Rho: Spearman's rank correlation coefficient, MFI (BioPlex): median fluorescent intensity and OD (ELISA): Optical density.
Percentage of individuals positive for IgG antibodies to PvMSP1 N- and C-termini in samples from PNG (Madang) and Brazil (Rio Machado) obtained by BioPlex assay.
| Samples from Madang | Samples from Rio Machado | |||
|---|---|---|---|---|
| Rec. protein | Classification | Classification | ||
| PvMSP1-N | 31 (31%) | S 15/50 (30%) | 77 (89%) | S 8/9 (89%) |
| AS 7/20 (35%) | AS 38/42 (90%) | |||
| N.I. 9/30 (30%) | N.I. 31/36 (86%) | |||
| PvMSP-C | 52 (52%) | S 28/50 (56%) | 70 (80%) | S 9/9 (100%) |
| AS 12/20 (60%) | AS 30/42 (71%) | |||
| N.I. 12/30 (40%) | N.I 31/36 (86%) | |||
S (symptomatic patients), AS (asymptomatic patients), N.I. (not infected).
Results of the multilevel logistic regression model showing different variables and their association with IgG antibodies to PvMSP1 N- and C- termini in samples from Brazil (Rio Machado) and Papua New Guinea (Madang).
| Samples from Rio Machado | Samples from Madang | |||||
|---|---|---|---|---|---|---|
| Variable | OR | 95%CI | p-value | OR | 95%CI | p-value |
| Classification | ||||||
| Non infected | 1 | 1 | (1.00-1.08) | |||
| Symptomatic | 1.29 | (0.13-12.66) | 1.00 | (0.37-2.69) | ||
| Asymptomatic | 1.53 | (0.38-6.20) | 0.835 | 1.26 | (0.38-4.20) | 0.911 |
| Sex | ||||||
| Female | 1 | |||||
| Male | 0.26 | (0.05-1.27) | 0.096 | n.d | ||
| Age (years) | ||||||
| Unit increment | 1.04 | (0.99-1.10) | 0.113 | 1.01 | (0.98-1.03) | 0.607 |
| Classification | ||||||
| Non infected | 1 | 1 | ||||
| Asymptomatic | 0.40 | (0.13-1.28) | 1.24 | 1.91 | (0.76-4.79) | |
| Symptomatic | 2.25 | (0.71-7.14) | 0.283 | |||
| Sex | ||||||
| Female | 1 | |||||
| Male | 1.65 | (0.60-4.55) | 0.336 | n.d | ||
| Age | ||||||
| Unit increment | 1.04 | (1.00-1.08) | 0.046 | 0.97 | (0.95-0.99) | 0.013 |
Figure 3IgG subclass profiles against PvMSP1-N and PvMSP1-C. A. Percentage of IgG subclass responses in Madang/Maprik (PNG). B. Percentage of IgG subclass responses in Rio Machado (Brazil).